Clinical Trial Update: Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione [Phase 3]

View source ↗

Summary

A Phase 3 trial assesses adding Amaryl (glimepiride) to non-insulin-dependent diabetes patients who are not adequately controlled on maximum-dose metformin and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Amaryl (glimepiride)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Non-Insulin-Dependent | Phase 3 | Status: COMPLETED